Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients

Exclusion Criteria

• •Current erythrodermic, generalized pustular, or guttate psoriasis
• •Serious local infection or systemic infection within 3 months prior to the first dose of alefacept
• •History of any clinical significant disease that would be contraindicated for this study as determined by the investigator
• •Prior history of systemic malignancy, untreated localised skin canceer or a \>10 squamous cell carcinoma
• •Current enrollment in any other investigational drug study within 30 days prior to study drug administration
• •Treatment with systemic immunosuppressant agents within the 4 weeks prior to study drug administration.